Biomarker-guided surveillance cuts cystoscopies in NMIBC without clear oncologic harm

Meta-analysis · World J Urol · 2026-11-16. Number 1 in the UrologyWatch Top 5 for November 16, 2026.

A meta-analysis of two randomized trials (DaBlaCa-15 and UroFollow, 606 patients, 590 in primary analyses) found biomarker-guided surveillance reduced cystoscopy use by 55.8% and 74.9% in the two trials respectively, with no significant difference in any recurrence (RR 1.04, 95% CI 0.77-1.41), high-grade recurrence or progression (RR 1.03, 95% CI 0.61-1.74), or progression to muscle-invasive/metastatic disease (RR 0.57, 95% CI 0.12-2.67); non-inferiority was not established.

Why it matters: Offers early randomized support for reducing cystoscopy burden in NMIBC surveillance, but confirmatory data are needed before changing guideline-based follow-up.

Limitation: Only two trials with 606 participants, differing surveillance protocols and risk groups, and few progression events limit the strength of conclusions.

Source: World J Urol · PubMed 43034244 · DOI 10.1007/s00345-026-06926-9

The full November 16, 2026 edition · Today's urology news

Loading today's edition…